Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy D...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: September 25, 2023

Statement by the Prime Minister on Yom Kippur • THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON • A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser • Unitedprint.com collaborates with Pexels.com • 2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS • France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival • Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize • PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE • No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty • 2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop • Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits • Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans • Wondershare FamiSafe 7.0 safeguarding Children with AI • Statement by Minister Khera on Yom Kippur • Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo • Intel Editorial: Intel Addresses Semiconductor Workforce Shortage • Guidewire Optimistic About New Direction of California Insurance • Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery • Reactive Technologies’ Grid Inertia Measurement Tech to Enable Offshore Wind Rollout in Taiwan • 65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders

Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study

SOUTH SAN FRANCISCO, Calif. , June 01 /Businesswire/ - Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and well-tolerated